Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense.

Pajic M, Froio D, Daly S, Doculara L, Millar E, Graham PH, Drury A, Steinmann A, de Bock CE, Boulghourjian A, Zaratzian A, Carroll S, Toohey J, O'Toole SA, Harris AL, Buffa FM, Gee HE, Hollway GE, Molloy TJ.

Cancer Res. 2018 Jan 15;78(2):501-515. doi: 10.1158/0008-5472.CAN-16-3105. Epub 2017 Nov 27.

PMID:
29180477
2.

Andy's Algorithms: new automated digital image analysis pipelines for FIJI.

Law AMK, Yin JXM, Castillo L, Young AIJ, Piggin C, Rogers S, Caldon CE, Burgess A, Millar EKA, O'Toole SA, Gallego-Ortega D, Ormandy CJ, Oakes SR.

Sci Rep. 2017 Nov 16;7(1):15717. doi: 10.1038/s41598-017-15885-6.

3.

LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness.

Pang JB, Molania R, Chand A, Knower K, Takano EA, Byrne DJ, Mikeska T, Millar EKA, Lee CS, O'Toole SA, Clyne C, Gorringe KL, Dobrovic A, Fox SB.

Oncotarget. 2017 Jul 28;8(48):83626-83636. doi: 10.18632/oncotarget.18886. eCollection 2017 Oct 13.

4.

Somatic mutations in salivary duct carcinoma and potential therapeutic targets.

Khoo TK, Yu B, Smith JA, Clarke AJ, Luk PP, Selinger CI, Mahon KL, Kraitsek S, Palme C, Boyer MJ, Dinger ME, Cowley MJ, O'Toole SA, Clark JR, Gupta R.

Oncotarget. 2017 May 25;8(44):75893-75903. doi: 10.18632/oncotarget.18173. eCollection 2017 Sep 29.

5.

Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.

Duivenvoorden HM, Rautela J, Edgington-Mitchell LE, Spurling A, Greening DW, Nowell CJ, Molloy TJ, Robbins E, Brockwell NK, Lee CS, Chen M, Holliday A, Selinger CI, Hu M, Britt KL, Stroud DA, Bogyo M, Möller A, Polyak K, Sloane BF, O'Toole SA, Parker BS.

J Pathol. 2017 Dec;243(4):496-509. doi: 10.1002/path.4990. Epub 2017 Oct 31.

PMID:
29086922
6.

The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.

Coulson R, Liew SH, Connelly AA, Yee NS, Deb S, Kumar B, Vargas AC, O'Toole SA, Parslow AC, Poh A, Putoczki T, Morrow RJ, Alorro M, Lazarus KA, Yeap EFW, Walton KL, Harrison CA, Hannan NJ, George AJ, Clyne CD, Ernst M, Allen AM, Chand AL.

Oncotarget. 2017 Mar 21;8(12):18640-18656. doi: 10.18632/oncotarget.15553.

7.

Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.

Pang JB, Savas P, Fellowes AP, Mir Arnau G, Kader T, Vedururu R, Hewitt C, Takano EA, Byrne DJ, Choong DY, Millar EK, Lee CS, O'Toole SA, Lakhani SR, Cummings MC, Mann GB, Campbell IG, Dobrovic A, Loi S, Gorringe KL, Fox SB.

Mod Pathol. 2017 Jul;30(7):952-963. doi: 10.1038/modpathol.2017.21. Epub 2017 Mar 24.

PMID:
28338653
8.

MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.

Young AI, Law AM, Castillo L, Chong S, Cullen HD, Koehler M, Herzog S, Brummer T, Lee EF, Fairlie WD, Lucas MC, Herrmann D, Allam A, Timpson P, Watkins DN, Millar EK, O'Toole SA, Gallego-Ortega D, Ormandy CJ, Oakes SR.

Breast Cancer Res. 2016 Dec 8;18(1):125.

9.

Case report of male breast cancer detected on magnetic resonance imaging.

Ryu SW, Ho K, O'Toole SA, Green A, Kim HW.

J Med Imaging Radiat Oncol. 2017 Jun;61(3):369-371. doi: 10.1111/1754-9485.12542. Epub 2016 Oct 5.

PMID:
27709811
10.

Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.

Selinger CI, Li BT, Pavlakis N, Links M, Gill AJ, Lee A, Clarke S, Tran TN, Lum T, Yip PY, Horvath L, Yu B, Kohonen-Corish MR, O'Toole SA, Cooper WA.

Histopathology. 2017 Feb;70(3):402-411. doi: 10.1111/his.13076. Epub 2016 Nov 15.

11.

Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases.

Vargas AC, Selinger CI, Satgunaseelan L, Cooper WA, Gupta R, Stalley P, Brown W, Soper J, Schatz J, Boyle R, Thomas DM, Tattersall MH, Bhadri VA, Maclean F, Bonar SF, Scolyer RA, Karim RZ, McCarthy SW, Mahar A, O'Toole SA.

Histopathology. 2016 Dec;69(6):1000-1011. doi: 10.1111/his.13031. Epub 2016 Sep 21.

PMID:
27385661
12.

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.

Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, O'Toole SA, Viale G, Van de Vijver K, de Wind R, von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R.

Mod Pathol. 2016 Oct;29(10):1155-64. doi: 10.1038/modpathol.2016.109. Epub 2016 Jul 1.

13.

PO-24 - Determinants of thrombin generation in gynaecological malignancies.

Norris LA, Martin FA, O'Toole SA, Saadeh FA, Gleeson N.

Thromb Res. 2016 Apr;140 Suppl 1:S185. doi: 10.1016/S0049-3848(16)30157-8. Epub 2016 Apr 8.

PMID:
27161714
14.

PO-14 - Tumour expression of coagulation proteases of the aPC pathway - a role in the pathogenesis of gynaecological cancers?

Martin F, Long JC, O'Toole SA, O'Leary JJ, Abu Saadeh F, Gleeson N, Norris LA.

Thromb Res. 2016 Apr;140 Suppl 1:S181. doi: 10.1016/S0049-3848(16)30147-5. Epub 2016 Apr 8.

PMID:
27161702
15.

OC-12 - Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice.

Petch S, Norris LA, O'Toole SA, Gleeson N, Saadeh FA.

Thromb Res. 2016 Apr;140 Suppl 1:S173. doi: 10.1016/S0049-3848(16)30129-3. Epub 2016 Apr 8.

PMID:
27161684
16.

BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.

Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E, Saw RP, Yu B, Cooper WA, Long GV, O'Toole SA, Scolyer RA.

Histopathology. 2016 Oct;69(4):680-6. doi: 10.1111/his.12992. Epub 2016 Jun 15.

PMID:
27151331
17.

Diagnostic and prognostic utility of Mastermind-like 2 (MAML2) gene rearrangement detection by fluorescent in situ hybridization (FISH) in mucoepidermoid carcinoma of the salivary glands.

Luk PP, Wykes J, Selinger CI, Ekmejian R, Tay J, Gao K, Eviston TJ, Lum T, O'Toole SA, Clark JR, Gupta R.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 May;121(5):530-41. doi: 10.1016/j.oooo.2016.01.003. Epub 2016 Jan 9.

PMID:
27068311
18.

The molecular profile of metastatic melanoma in Australia.

Lyle M, Haydu LE, Menzies AM, Thompson JF, Saw RP, Spillane AJ, Kefford RF, Mann GJ, Cooper WA, Yu B, Scolyer RA, O'Toole SA, Long GV.

Pathology. 2016 Feb;48(2):188-93. doi: 10.1016/j.pathol.2015.12.008. Epub 2016 Jan 18.

PMID:
27020391
19.

Liposarcoma masquerading as an inflammatory pseudotumor: a case report.

Reagh JJ, Eckstein RP, Selinger CI, Evans J, O'Toole SA, Gill AJ.

J Med Case Rep. 2016 Mar 18;10:64. doi: 10.1186/s13256-016-0858-y.

20.

Somatic DNA mutation analysis in targeted therapy of solid tumours.

Yu B, O'Toole SA, Trent RJ.

Transl Pediatr. 2015 Apr;4(2):125-38. doi: 10.3978/j.issn.2224-4336.2015.04.04. Review.

21.

Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.

Luk PP, Weston JD, Yu B, Selinger CI, Ekmejian R, Eviston TJ, Lum T, Gao K, Boyer M, O'Toole SA, Clark JR, Gupta R.

Head Neck. 2016 Apr;38 Suppl 1:E1838-47. doi: 10.1002/hed.24332. Epub 2015 Dec 24.

PMID:
26699379
22.

Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.

Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, Kennedy CW, Gluch L, Carmalt H, Mak C, Warrier S, Gee HE, Chan C, McLean A, Walker E, McNeil CM, Beith JM, Swarbrick A, Scolyer RA, O'Toole SA.

Histopathology. 2016 Jul;69(1):25-34. doi: 10.1111/his.12904. Epub 2016 Jan 13.

PMID:
26588661
23.

MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer.

Gee HE, Buffa FM, Harris AL, Toohey JM, Carroll SL, Cooper CL, Beith J, McNeil C, Carmalt H, Mak C, Warrier S, Holliday A, Selinger C, Beckers R, Kennedy C, Graham P, Swarbrick A, Millar EK, O'Toole SA, Molloy T.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1104-14. doi: 10.1016/j.ijrobp.2015.08.046. Epub 2015 Sep 3.

PMID:
26581147
24.

Mammary analogue secretory carcinoma: an evaluation of its clinicopathological and genetic characteristics.

Luk PP, Selinger CI, Eviston TJ, Lum T, Yu B, O'Toole SA, Clark JR, Gupta R.

Pathology. 2015 Dec;47(7):659-66. doi: 10.1097/PAT.0000000000000322.

PMID:
26517645
25.

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.

van Geldermalsen M, Wang Q, Nagarajah R, Marshall AD, Thoeng A, Gao D, Ritchie W, Feng Y, Bailey CG, Deng N, Harvey K, Beith JM, Selinger CI, O'Toole SA, Rasko JE, Holst J.

Oncogene. 2016 Jun 16;35(24):3201-8. doi: 10.1038/onc.2015.381. Epub 2015 Oct 12.

26.

Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.

Tran TN, Selinger CI, Kohonen-Corish MR, McCaughan B, Kennedy C, O'Toole SA, Cooper WA.

Clin Lung Cancer. 2016 Jan;17(1):30-8.e1. doi: 10.1016/j.cllc.2015.08.002. Epub 2015 Aug 18.

PMID:
26395411
27.

Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.

McEvoy LM, O'Toole SA, Spillane CD, Martin CM, Gallagher MF, Stordal B, Blackshields G, Sheils O, O'Leary JJ.

BMC Cancer. 2015 Jul 25;15:547. doi: 10.1186/s12885-015-1539-8.

28.

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA.

Lung Cancer. 2015 Aug;89(2):181-8. doi: 10.1016/j.lungcan.2015.05.007. Epub 2015 May 18.

PMID:
26024796
29.

BRAF mutations in non-small cell lung cancer.

Luk PP, Yu B, Ng CC, Mercorella B, Selinger C, Lum T, Kao S, O'Toole SA, Cooper WA.

Transl Lung Cancer Res. 2015 Apr;4(2):142-8. doi: 10.3978/j.issn.2218-6751.2014.08.08.

30.

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer.

Wang S, Yu B, Ng CC, Mercorella B, Selinger CI, O'Toole SA, Cooper WA.

Transl Lung Cancer Res. 2015 Apr;4(2):119-25. doi: 10.3978/j.issn.2218-6751.2015.01.05.

31.

A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma.

Chou A, Fraser S, Toon CW, Clarkson A, Sioson L, Farzin M, Cussigh C, Aniss A, O'Neill C, Watson N, Clifton-Bligh RJ, Learoyd DL, Robinson BG, Selinger CI, Delbridge LW, Sidhu SB, O'Toole SA, Sywak M, Gill AJ.

Am J Surg Pathol. 2015 May;39(5):652-9. doi: 10.1097/PAS.0000000000000368.

32.

Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features.

Pang JM, Deb S, Takano EA, Byrne DJ, Jene N, Boulghourjian A, Holliday A, Millar E, Lee CS, O'Toole SA, Dobrovic A, Fox SB.

Breast Cancer Res. 2014 Oct 21;16(5):423. doi: 10.1186/s13058-014-0423-9.

33.

EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.

Houang M, Sioson L, Clarkson A, Watson N, Farzin M, Toon CW, Raut A, O'Toole SA, Cooper WA, Pavlakis N, Mead S, Chou A, Gill AJ.

Pathology. 2014 Oct;46(6):501-8. doi: 10.1097/PAT.0000000000000141.

PMID:
25158821
34.

Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer.

Tran TN, Selinger CI, Yu B, Ng CC, Kohonen-Corish MR, McCaughan B, Kennedy C, O'Toole SA, Cooper WA.

J Clin Pathol. 2014 Nov;67(11):985-91. doi: 10.1136/jclinpath-2014-202347. Epub 2014 Aug 12.

PMID:
25118293
35.

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, Scolyer RA, Long GV.

Br J Cancer. 2014 Jul 15;111(2):292-9. doi: 10.1038/bjc.2014.287. Epub 2014 Jun 10.

36.

Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer.

Houang M, Toon CW, Clarkson A, Sioson L, Watson N, Farzin M, Selinger CI, Chou A, Morey AL, Cooper WA, O'Toole SA, Gill AJ.

Pathology. 2014 Aug;46(5):383-8. doi: 10.1097/PAT.0000000000000114.

PMID:
24842379
37.

Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.

Kakavand H, Crainic O, Lum T, O'Toole SA, Kefford RF, Thompson JF, Wilmott JS, Long GV, Scolyer RA.

Pathology. 2014 Apr;46(3):193-8. doi: 10.1097/PAT.0000000000000077.

PMID:
24614711
38.

Molecular biology of lung cancer.

Cooper WA, Lam DC, O'Toole SA, Minna JD.

J Thorac Dis. 2013 Oct;5 Suppl 5:S479-90. doi: 10.3978/j.issn.2072-1439.2013.08.03. Review.

39.

c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.

Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, Nguyen A, Yang J, Nikolic I, Hui M, Morey A, Shah J, Pfefferle AD, Usary J, Selinger C, Baker LA, Armstrong N, Cowley MJ, Naylor MJ, Ormandy CJ, Lakhani SR, Herschkowitz JI, Perou CM, Kaplan W, O'Toole SA, Swarbrick A.

Oncogene. 2014 Jul 24;33(30):3992-4002. doi: 10.1038/onc.2013.368. Epub 2013 Sep 23.

PMID:
24056965
40.

Transcription factor ATF3 links host adaptive response to breast cancer metastasis.

Wolford CC, McConoughey SJ, Jalgaonkar SP, Leon M, Merchant AS, Dominick JL, Yin X, Chang Y, Zmuda EJ, O'Toole SA, Millar EK, Roller SL, Shapiro CL, Ostrowski MC, Sutherland RL, Hai T.

J Clin Invest. 2013 Jul;123(7):2893-906. doi: 10.1172/JCI64410. Epub 2013 Jun 10.

41.

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

Browne BC, Hochgräfe F, Wu J, Millar EK, Barraclough J, Stone A, McCloy RA, Lee CS, Roberts C, Ali NA, Boulghourjian A, Schmich F, Linding R, Farrow L, Gee JM, Nicholson RI, O'Toole SA, Sutherland RL, Musgrove EA, Butt AJ, Daly RJ.

FEBS J. 2013 Nov;280(21):5237-57. doi: 10.1111/febs.12441. Epub 2013 Aug 19.

42.

Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.

Tran TN, Selinger CI, Kohonen-Corish MR, McCaughan BC, Kennedy CW, O'Toole SA, Cooper WA.

Lung Cancer. 2013 Sep;81(3):462-7. doi: 10.1016/j.lungcan.2013.05.015. Epub 2013 Jun 24.

PMID:
23806793
43.

EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.

Cooper WA, Yu B, Yip PY, Ng CC, Lum T, Farzin M, Trent RJ, Mercorella B, Clarkson A, Kohonen-Corish MR, Horvath LG, Kench JG, McCaughan B, Gill AJ, O'Toole SA.

J Clin Pathol. 2013 Sep;66(9):744-8. doi: 10.1136/jclinpath-2013-201607. Epub 2013 Jun 11.

PMID:
23757037
44.

β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.

Schade B, Lesurf R, Sanguin-Gendreau V, Bui T, Deblois G, O'Toole SA, Millar EK, Zardawi SJ, Lopez-Knowles E, Sutherland RL, Giguère V, Kahn M, Hallett M, Muller WJ.

Cancer Res. 2013 Jul 15;73(14):4474-87. doi: 10.1158/0008-5472.CAN-12-3925. Epub 2013 May 29.

45.

Breast pathology today: morphology and molecules.

Rakha EA, O'Toole SA, Ellis IO, Tan PH.

J Clin Pathol. 2013 Jun;66(6):457. doi: 10.1136/jclinpath-2013-201660. No abstract available.

PMID:
23703974
46.

The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy.

Hui M, Cazet A, Nair R, Watkins DN, O'Toole SA, Swarbrick A.

Breast Cancer Res. 2013 Mar 28;15(2):203. doi: 10.1186/bcr3401. Review.

47.

Classification, morphology and molecular pathology of premalignant lesions of the pancreas.

Cooper CL, O'Toole SA, Kench JG.

Pathology. 2013 Apr;45(3):286-304. doi: 10.1097/PAT.0b013e32835f2205. Review.

PMID:
23442735
48.

Therapeutic targets in triple negative breast cancer.

O'Toole SA, Beith JM, Millar EK, West R, McLean A, Cazet A, Swarbrick A, Oakes SR.

J Clin Pathol. 2013 Jun;66(6):530-42. doi: 10.1136/jclinpath-2012-201361. Epub 2013 Feb 22. Review.

PMID:
23436929
49.

Recent insights into the molecular pathogenesis of mammary phyllodes tumours.

Karim RZ, O'Toole SA, Scolyer RA, Cooper CL, Chan B, Selinger C, Yu B, Carmalt H, Mak C, Tse GM, Tan PH, Putti TC, Lee CS.

J Clin Pathol. 2013 Jun;66(6):496-505. doi: 10.1136/jclinpath-2012-201082. Epub 2013 Feb 12. Review.

PMID:
23404800
50.

Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.

Yip PY, Yu B, Cooper WA, Selinger CI, Ng CC, Kennedy CW, Kohonen-Corish MR, McCaughan BC, Trent RJ, Boyer MJ, Kench JG, Horvath LG, O'Toole SA.

J Thorac Oncol. 2013 Apr;8(4):408-14. doi: 10.1097/JTO.0b013e318283558e.

Supplemental Content

Loading ...
Support Center